Rockefeller Capital Management’s Humacyte HUMA Stock Holding History

Rockefeller Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.46K	Sell	7,000 -3,150	-31%	-$2.92K	﹤0.01%	4212
2026 Q1	$6.16K	Buy	10,150 +9,880	+3,659%	+$10.3K	﹤0.01%	4186
2025 Q4	$259	Hold	270	–	–	﹤0.01%	4576
2025 Q3	$470	Buy	+270	New	+$529	﹤0.01%	4275
2025 Q2	–	Sell	-370,148	Closed	-$631K	–	1755
2025 Q1	$631K	Buy	370,148 +320,486	+645%	+$1.2M	﹤0.01%	1411
2024 Q4	$251K	Buy	+49,662	New	+$246K	﹤0.01%	1621
2021 Q2	–	Sell	-500	Closed	-$5K	–	3511
2021 Q1	$5K	Buy	+500	New	+$5.46K	﹤0.01%	2891

Other funds holding HUMA

Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Rockefeller Capital Management's HUMA Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Humacyte (HUMA) stake by 31% in Q2 2026, selling an estimated $2.92K and leaving 7,000 shares worth $5.46K. The position accounts for ﹤0.01% of the portfolio, ranked #4212.

Rockefeller Capital Management first reported a position in HUMA in Q1 2021 and has held it in 7 quarters since. The position peaked at $631K in Q1 2025. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

Rockefeller Capital Management held 7,000 shares of Humacyte worth $5.46K as of Q2 2026.
Rockefeller Capital Management sold 3,150 Humacyte shares in Q2 2026, an estimated $2.92K.
Humacyte made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4212 holding.
Rockefeller Capital Management first reported a position in Humacyte in Q1 2021 and has held it in 7 quarters since.
Rockefeller Capital Management's Humacyte position peaked at $631K in Q1 2025.
161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.